Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Symrise

This article was originally published in The Rose Sheet

Executive Summary

James Forman appointed CEO and president of flavors and fragrance supplier as company moves beyond integration phase into preparing for an initial public offering within the next three to four years, Holzminden, Germany firm reports Sept. 15. Effective Oct. 1, Forman will succeed Horst-Otto Gerberding, who will become vice chairman of the board. Gerberding's role as CEO and president was intended as an interim position during the integration phase of the Dragoco and Haarmann & Reimer businesses (1"The Rose Sheet" Oct. 14, 2002, In Brief). Gerberding will continue to help oversee the company's strategic direction and position it for the IPO. Forman most recently served as CEO of consumer products company Stollwerck AG...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel